Orient Pharma Co., Ltd. (TPEX:4166)
Taiwan · Delayed Price · Currency is TWD 36.05
-0.55 (-1.50%)
Jul 18, 2025, 1:57 PM CST
Orient Pharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 1,264 | 1,223 | 889.91 | 511.86 | 463.34 | 412.01 | Upgrade | |
Revenue Growth (YoY) | 32.71% | 37.41% | 73.86% | 10.47% | 12.46% | 16.54% | Upgrade |
Cost of Revenue | 607.34 | 571.26 | 421.25 | 356.51 | 320.67 | 336.86 | Upgrade |
Gross Profit | 656.44 | 651.56 | 468.67 | 155.35 | 142.67 | 75.15 | Upgrade |
Selling, General & Admin | 380.87 | 373.93 | 341.01 | 67.83 | 56.45 | 57.97 | Upgrade |
Research & Development | 101.84 | 103.72 | 99.9 | 129.25 | 219.72 | 183.94 | Upgrade |
Operating Expenses | 484.79 | 493.65 | 444.35 | 197.09 | 276.16 | 241.91 | Upgrade |
Operating Income | 171.64 | 157.91 | 24.32 | -41.74 | -133.49 | -166.75 | Upgrade |
Interest Expense | -13.06 | -13.97 | -13.9 | -7.37 | -5.7 | -5.38 | Upgrade |
Interest & Investment Income | 3.41 | 3.62 | 1.68 | 1.09 | 0.52 | 0.41 | Upgrade |
Currency Exchange Gain (Loss) | 7.01 | 5.62 | 1.07 | 5.31 | 1.25 | 0.91 | Upgrade |
Other Non Operating Income (Expenses) | 9.7 | 9.94 | 9.79 | 1.72 | 37.33 | 5.17 | Upgrade |
EBT Excluding Unusual Items | 178.7 | 163.12 | 22.95 | -40.99 | -100.09 | -165.65 | Upgrade |
Gain (Loss) on Sale of Assets | -0.13 | - | -0.04 | -0.13 | - | - | Upgrade |
Asset Writedown | - | - | - | - | -10 | - | Upgrade |
Other Unusual Items | - | - | 0.01 | 0.01 | - | - | Upgrade |
Pretax Income | 178.57 | 163.12 | 22.92 | -41.11 | -110.09 | -165.65 | Upgrade |
Income Tax Expense | 58.63 | 55.75 | 0.64 | -12.35 | -7.44 | 5.73 | Upgrade |
Net Income | 119.94 | 107.37 | 22.29 | -28.76 | -102.65 | -171.38 | Upgrade |
Net Income to Common | 119.94 | 107.37 | 22.29 | -28.76 | -102.65 | -171.38 | Upgrade |
Net Income Growth | 99.25% | 381.76% | - | - | - | - | Upgrade |
Shares Outstanding (Basic) | 223 | 223 | 223 | 187 | 187 | 169 | Upgrade |
Shares Outstanding (Diluted) | 223 | 223 | 223 | 187 | 187 | 169 | Upgrade |
Shares Change (YoY) | - | - | 19.27% | -0.00% | 10.40% | 8.57% | Upgrade |
EPS (Basic) | 0.54 | 0.48 | 0.10 | -0.15 | -0.55 | -1.01 | Upgrade |
EPS (Diluted) | 0.54 | 0.48 | 0.10 | -0.15 | -0.55 | -1.01 | Upgrade |
EPS Growth | 99.25% | 381.76% | - | - | - | - | Upgrade |
Free Cash Flow | 283.45 | 169.68 | -157.1 | -17.01 | -120.1 | -222.38 | Upgrade |
Free Cash Flow Per Share | 1.27 | 0.76 | -0.70 | -0.09 | -0.64 | -1.31 | Upgrade |
Gross Margin | 51.94% | 53.28% | 52.66% | 30.35% | 30.79% | 18.24% | Upgrade |
Operating Margin | 13.58% | 12.91% | 2.73% | -8.15% | -28.81% | -40.47% | Upgrade |
Profit Margin | 9.49% | 8.78% | 2.50% | -5.62% | -22.16% | -41.59% | Upgrade |
Free Cash Flow Margin | 22.43% | 13.88% | -17.65% | -3.32% | -25.92% | -53.97% | Upgrade |
EBITDA | 278.36 | 272.67 | 138.97 | 12.43 | -82.31 | -114.32 | Upgrade |
EBITDA Margin | 22.03% | 22.30% | 15.62% | 2.43% | -17.76% | -27.75% | Upgrade |
D&A For EBITDA | 106.71 | 114.76 | 114.65 | 54.17 | 51.18 | 52.43 | Upgrade |
EBIT | 171.64 | 157.91 | 24.32 | -41.74 | -133.49 | -166.75 | Upgrade |
EBIT Margin | 13.58% | 12.91% | 2.73% | -8.15% | -28.81% | -40.47% | Upgrade |
Effective Tax Rate | 32.84% | 34.18% | 2.77% | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.